147 related articles for article (PubMed ID: 34930267)
1. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Jain JP; Barsainya S; Kullak-Ublick GA; Su G; Schmitt EK; Csermak K; Gandhi P; Hughes D
Malar J; 2021 Dec; 20(1):478. PubMed ID: 34930267
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria.
Schmitt EK; Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Su G; Csermak Renner K; Venishetty VK; Sayyed S; Straimer J; Demin I; Barsainya S; Boulton C; Gandhi P
Clin Infect Dis; 2022 May; 74(10):1831-1839. PubMed ID: 34410358
[TBL] [Abstract][Full Text] [Related]
3. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
Straimer J; Gandhi P; Renner KC; Schmitt EK
J Infect Dis; 2022 Apr; 225(8):1411-1414. PubMed ID: 34216470
[TBL] [Abstract][Full Text] [Related]
4. Spiroindolone KAE609 for falciparum and vivax malaria.
White NJ; Pukrittayakamee S; Phyo AP; Rueangweerayut R; Nosten F; Jittamala P; Jeeyapant A; Jain JP; Lefèvre G; Li R; Magnusson B; Diagana TT; Leong FJ
N Engl J Med; 2014 Jul; 371(5):403-10. PubMed ID: 25075833
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.
Hien TT; White NJ; Thuy-Nhien NT; Hoa NT; Thuan PD; Tarning J; Nosten F; Magnusson B; Jain JP; Hamed K
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872070
[TBL] [Abstract][Full Text] [Related]
7. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Pryce J; Hine P
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD006404. PubMed ID: 30620055
[TBL] [Abstract][Full Text] [Related]
8. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
[TBL] [Abstract][Full Text] [Related]
9. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Pilot Trial to Evaluate
Noudjiegbe AN; Alikekere FN; Tchehouenou H; Langa Y; Ota DS; Degbelo JE; Allabi ACE
Evid Based Complement Alternat Med; 2020; 2020():8715021. PubMed ID: 32215047
[TBL] [Abstract][Full Text] [Related]
11. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Pryce J; Taylor M; Fox T; Hine P
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD006404. PubMed ID: 35726133
[TBL] [Abstract][Full Text] [Related]
12. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
[TBL] [Abstract][Full Text] [Related]
13. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.
Sirima SB; Ogutu B; Lusingu JPA; Mtoro A; Mrango Z; Ouedraogo A; Yaro JB; Onyango KO; Gesase S; Mnkande E; Ngocho JS; Ackermann I; Aubin F; Vanraes J; Strub N; Carn G
Lancet Infect Dis; 2016 Oct; 16(10):1123-1133. PubMed ID: 27430374
[TBL] [Abstract][Full Text] [Related]
14. Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.
Ndiaye JL; Randrianarivelojosia M; Sagara I; Brasseur P; Ndiaye I; Faye B; Randrianasolo L; Ratsimbasoa A; Forlemu D; Moor VA; Traore A; Dicko Y; Dara N; Lameyre V; Diallo M; Djimde A; Same-Ekobo A; Gaye O
Malar J; 2009 Jun; 8():125. PubMed ID: 19505304
[TBL] [Abstract][Full Text] [Related]
15. Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial.
Mhamilawa LE; Ngasala B; Morris U; Kitabi EN; Barnes R; Soe AP; Mmbando BP; Björkman A; Mårtensson A
Malar J; 2020 Jun; 19(1):216. PubMed ID: 32576258
[TBL] [Abstract][Full Text] [Related]
16. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.
Yavo W; Faye B; Kuete T; Djohan V; Oga SA; Kassi RR; Diatta M; Ama MV; Tine R; Ndiaye JL; Evi JB; Same-Ekobo A; Faye O; Koné M
Malar J; 2011 Jul; 10():198. PubMed ID: 21774826
[TBL] [Abstract][Full Text] [Related]
17. Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study.
Tona Lutete G; Mombo-Ngoma G; Assi SB; Bigoga JD; Koukouikila-Koussounda F; Ntamabyaliro NY; Ntoumi F; Agnandji ST; Groger M; Shin J; Borghini-Fuhrer I; Arbe-Barnes S; Allen SJ; Kremsner PG; Miller R; Duparc S; Ramharter M;
PLoS Med; 2021 Jun; 18(6):e1003669. PubMed ID: 34129601
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
[TBL] [Abstract][Full Text] [Related]
19. Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.
Ogutu B; Yeka A; Kusemererwa S; Thompson R; Tinto H; Toure AO; Uthaisin C; Verma A; Kibuuka A; Lingani M; Lourenço C; Mombo-Ngoma G; Nduba V; N'Guessan TL; Nassa GJW; Nyantaro M; Tina LO; Singh PK; El Gaaloul M; Marrast AC; Chikoto H; Csermak K; Demin I; Mehta D; Pathan R; Risterucci C; Su G; Winnips C; Kaguthi G; Fofana B; Grobusch MP
Lancet Infect Dis; 2023 Sep; 23(9):1051-1061. PubMed ID: 37327809
[TBL] [Abstract][Full Text] [Related]
20. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.
Koita OA; Sangaré L; Miller HD; Sissako A; Coulibaly M; Thompson TA; Fongoro S; Diarra Y; Ba M; Maiga A; Diallo B; Mushatt DM; Mather FJ; Shaffer JG; Anwar AH; Krogstad DJ
Lancet Infect Dis; 2017 Dec; 17(12):1266-1275. PubMed ID: 28916443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
